EUVIMEDEUVIMED entdecken
Crossref

IP6K1 Rewires LKB1 Signaling to Mediate Hyperglycemic Endothelial Senescence

Changchang Xing iD, Linhui Shi, Limei Zhu, Tim Aguirre, Ji Qi, Yuanyuan Chen, Yue Liu, Alfred C Chin, Hong Zhu, Dorothea Fiedler, Alex F Chen, Chenglai Fu

Diabetes · 2025

DOI: 10.2337/db24-0706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Changchang Xing und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Developmental and Regenerative Cardiovascular Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Ch…. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cellular Senescence, Hyperglycemia, Endothelial Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, NIH Medical Scientist Training Program Training Grant, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes is a major risk factor for cardiovascular disease, but the molecular mechanisms underlying diabetic vasculopathy have been elusive. Here we report that inositol hexakisphosphate kinase 1 (IP6K1) mediates hyperglycemia-induced endothelial senescence by rewiring liver kinase B1 (LKB1) signaling from the AMPK pathway to the p53 pathway. We found that hyperglycemia upregulated IP6K1, which disrupted Hsp/Hsc70 and carboxyl terminus of Hsc70-interacting protein–mediated LKB1 degradation, leading to increased expression levels of LKB1. High glucose also strengthened the binding of IP6K1 to AMPK, suppressing LKB1-mediated AMPK activation. Thus, elevated LKB1 did not lead to activation of the AMPK pathway. Instead, it bound more to p53, resulting in p53-dependent endothelial senescence. Endothelial cell–specific deletion of IP6K1 alleviated, whereas endothelial cell–specific overexpression of IP6K1 exaggerated, hyperglycemia-induced endothelial senescence. This study reveals a regulatory mechanism of IP6K1 in switching LKB1 activation of the AMPK pathway to activation of the p53 pathway. IP6K1 represents a potential therapeutic target for treating hyperglycemia-induced endothelial dysfunction. Article Highlights Diabetes is a major risk factor for cardiovascular diseases. The mechanisms of hyperglycemia-induced endothelial dysfunction have been elusive. We found that inositol hexakisphosphate kinase 1 (IP6K1) mediates hyperglycemia-induced endothelial senescence by switching liver kinase B1 (LKB1) activation of the AMPK pathway to activation of the p53 pathway. Hyperglycemia upregulates IP6K1, which stabilizes LKB1 by disrupting Hsp/Hsc70 and carboxyl terminus of Hsc70-interacting protein–mediated LKB1 degradation but suppresses LKB1-dependent AMPK activation. Elevated LKB1 binds more to p53, resulting in p53-dependent endothelial senescence. Endothelial cell–specific deletion of IP6K1 attenuates, whereas endothelial cell–specific overexpression of IP6K1 exaggerates, hyperglycemia-induced endothelial senescence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesCellular SenescenceHyperglycemiaEndothelial CellsPhosphotransferases (Phosphate Group Acceptor)Signal TransductionHumansAnimalsAMP-Activated Protein Kinase KinasesMiceAMP-Activated Protein KinasesTumor Suppressor Protein p53

Substanzen

Protein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesSTK11 protein, humanAMP-Activated Protein KinasesTumor Suppressor Protein p53Phosphotransferases (Phosphate Group Acceptor)Stk11 protein, mouse

Autor:innen und Institutionen

  • Institute for Developmental and Regenerative Cardiovascular Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Critical Care Unit, Ningbo Medical Center Lihuili Hospital, Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
  • Department of Trauma Orthopedics, Ningbo No. 6 Hospital, Ningbo, China.
  • Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
  • Tri-Institutional MD-PhD Program, Weill Cornell Medical College, Rockefeller University, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Changchang Xing

Förderung

  • National Natural Science Foundation of China
  • NIH Medical Scientist Training Program Training Grant
  • National Key Research and Development Program of China
  • Ministry of Science and Technology of China

Zitieren

APA

Xing, C., Shi, L., Zhu, L., Aguirre, T., Qi, J., Chen, Y., Liu, Y., Chin, A. C., Zhu, H., Fiedler, D., Chen, A. F., & Fu, C. (2025). IP6K1 Rewires LKB1 Signaling to Mediate Hyperglycemic Endothelial Senescence. Diabetes. https://doi.org/10.2337/db24-0706

Vancouver

Xing C, Shi L, Zhu L, Aguirre T, Qi J, Chen Y, et al. IP6K1 Rewires LKB1 Signaling to Mediate Hyperglycemic Endothelial Senescence. Diabetes. 2025. doi:10.2337/db24-0706

BibTeX
@article{Xing2025,
  author = {Xing, Changchang and Shi, Linhui and Zhu, Limei and Aguirre, Tim and Qi, Ji and Chen, Yuanyuan and Liu, Yue and Chin, Alfred C and Zhu, Hong and Fiedler, Dorothea and Chen, Alex F and Fu, Chenglai},
  title = {IP6K1 Rewires LKB1 Signaling to Mediate Hyperglycemic Endothelial Senescence},
  journal = {Diabetes},
  year = {2025},
  doi = {10.2337/db24-0706}
}
Kostenlos starten →